<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858063</url>
  </required_header>
  <id_info>
    <org_study_id>KALICOU2-0909</org_study_id>
    <nct_id>NCT02858063</nct_id>
  </id_info>
  <brief_title>Psychometric Validation (Quality-of-life Scale) in Young Women With a Non Metastatic Breast Cancer and Her Partner</brief_title>
  <acronym>KALICOU2</acronym>
  <official_title>Psychometric Validation of a Subjective Quality-of-life Scale in Young Women With a Non Metastatic Breast Cancer and Her Partner (KALICOU 2 Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Lille 3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Selection of patient and preparation of questionnaires

        -  Presentation of the study by the doctor

        -  Verbal consent of participants (patient and Partner)

        -  Delivery of booklets

        -  Response to documents (questionnaires and written consent) at home, send by mail
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Before consultation :

           Selection of patients according to inclusion criteria by persons in charge and
           preparation of inclusion file

        2. During the consultation :

             -  Presentation of the study by the investigator

             -  The investigator signs the information note and give two file to the patient (1 for
                her and 1 for her Partner : both contains 1 information note signed by the
                investigator, 1 questionnaire and 2 stamped envelopes

             -  Finally, the investigator fill-in the medical form and send the original to the
                university (université de Lille 3)

        3. At home :

             -  Signature of the information note and the participation consent form

             -  Patients and Partner responds to their questionnaire (including socio-demographique
                questionnaire)

             -  They send the documents thanks to stamped envelopes:

                  1. They send information note to the medical center

                  2. They send the questionnaires to the university
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>psychometric validation of a questionnaire in Young patients and their partners</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare convergent and or divergent dimensions with patients and theirs partners</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare responses of participants according to traitement/ surveillance period</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1045</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pending chemotherapy +/- trastuzumab</arm_group_label>
    <description>In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pending trastazumab +/- hormone therapy</arm_group_label>
    <description>In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pending hormone therapy alone</arm_group_label>
    <description>In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pending afercare period</arm_group_label>
    <description>In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Young women (&lt;45 years old)treated or previously treated by chemotherapy for a non
        metastatic breast cancer, in Relationship for at least 6 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old (patient and partner)

          -  &lt;45 years old (patient)

          -  Patient with a non metastatic breast cancer

          -  Patient treated or previously treated by chemotherapy

          -  Patient and her Partner live together for at least 6 months when they complete the
             questionnaires.

        Exclusion Criteria:

          -  Patient or patner with psychiatric trouble

          -  Native language other than french
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Quality Of Life</keyword>
  <keyword>Women</keyword>
  <keyword>Partner</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

